Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. Reinisch W, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2019 Jan 1;25(1):163-171. doi: 10.1093/ibd/izy229. Inflamm Bowel Dis. 2019. PMID: 29982631 Clinical Trial.
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. Reinisch W, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2007 Sep;13(9):1135-40. doi: 10.1002/ibd.20165. Inflamm Bowel Dis. 2007. PMID: 17476675 Clinical Trial.
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. Reinisch W, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2012 Feb;18(2):201-11. doi: 10.1002/ibd.21697. Epub 2011 Apr 11. Inflamm Bowel Dis. 2012. PMID: 21484965 Clinical Trial.
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group. Sandborn WJ, et al. Among authors: rutgeerts p. Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2. Gastroenterology. 2014. PMID: 23735746 Clinical Trial.
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group. Sandborn WJ, et al. Among authors: rutgeerts p. Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14. Gastroenterology. 2014. PMID: 23770005 Clinical Trial.
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
Bouguen G, Sninsky C, Tang KL, Colombel JF, DʼHaens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn WJ. Bouguen G, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2015 Mar;21(3):606-14. doi: 10.1097/MIB.0000000000000302. Inflamm Bowel Dis. 2015. PMID: 25581826 Clinical Trial.
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
Eser A, Colombel JF, Rutgeerts P, Vermeire S, Vogelsang H, Braddock M, Persson T, Reinisch W. Eser A, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2015 Oct;21(10):2247-53. doi: 10.1097/MIB.0000000000000514. Inflamm Bowel Dis. 2015. PMID: 26197451 Clinical Trial.
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ. Adedokun OJ, et al. Among authors: rutgeerts p. J Crohns Colitis. 2017 Jan;11(1):35-46. doi: 10.1093/ecco-jcc/jjw133. Epub 2016 Jul 20. J Crohns Colitis. 2017. PMID: 27440869 Free PMC article. Clinical Trial.
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM. Feagan B, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2018 Apr 23;24(5):932-942. doi: 10.1093/ibd/izx082. Inflamm Bowel Dis. 2018. PMID: 29668919 Clinical Trial.
727 results